SK105698A3 - Method of treatment and pharmaceutical composion - Google Patents

Method of treatment and pharmaceutical composion Download PDF

Info

Publication number: SK105698A3
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; phenyl; loratidine; leukotriene antagonist; ethenyl
Prior art date: 1996-02-08

Application number

SK1056-98A

Other languages

English (en)

Slovak (sk)

Inventor

Sven-Erik Dahlen

Edward M Scolnick

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-08

Filing date

1997-02-04

Publication date

1999-05-07

1996-04-29 Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en

1997-02-04 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1999-05-07 Publication of SK105698A3 publication Critical patent/SK105698A3/sk

Links

238000000034 method Methods 0.000 title abstract description 3
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
229960003088 loratadine Drugs 0.000 claims abstract description 16
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 16
239000003199 leukotriene receptor blocking agent Substances 0.000 claims abstract description 15
206010020751 Hypersensitivity Diseases 0.000 claims abstract description 7
206010061218 Inflammation Diseases 0.000 claims abstract description 6
230000007815 allergy Effects 0.000 claims abstract description 6
208000006673 asthma Diseases 0.000 claims abstract description 6
230000004054 inflammatory process Effects 0.000 claims abstract description 6
208000026935 allergic disease Diseases 0.000 claims abstract description 5
LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 6
-1 3- (2- (6,7-Difluoro-2-quinolinyl) ethenyl) phenyl Chemical group 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
229960001951 montelukast sodium Drugs 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims description 3
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 3
MXCOXRCQSNVLRE-UHFFFAOYSA-M C(C)(=O)[O-].[Na+].C1CC1 Chemical compound C(C)(=O)[O-].[Na+].C1CC1 MXCOXRCQSNVLRE-UHFFFAOYSA-M 0.000 claims description 3
229960004583 pranlukast Drugs 0.000 claims description 3
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 2
239000002131 composite material Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
229960004764 zafirlukast Drugs 0.000 claims 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
OQFHCJMOQCAFIL-UHFFFAOYSA-N acetic acid;cyclopropane Chemical compound C1CC1.CC(O)=O OQFHCJMOQCAFIL-UHFFFAOYSA-N 0.000 claims 1
239000006186 oral dosage form Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000203 mixture Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000008213 purified water Substances 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
241000792859 Enema Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
239000008358 core component Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1056-98A 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion SK105698A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1132896P	1996-02-08	1996-02-08
GBGB9608927.1A GB9608927D0 (en)	1996-04-29	1996-04-29	Method of treatment and pharmaceutical composition
PCT/US1997/001799 WO1997028797A1 (en)	1996-02-08	1997-02-04	Method of treatment and pharmaceutical composion

Publications (1)

Publication Number	Publication Date
SK105698A3 true SK105698A3 (en)	1999-05-07

Family

ID=26309231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1056-98A SK105698A3 (en)	1996-02-08	1997-02-04	Method of treatment and pharmaceutical composion

Country Status (19)

Country	Link
EP (1)	EP1014972A4 (et)
JP (1)	JPH11504044A (et)
KR (1)	KR19990082367A (et)
CN (1)	CN1210465A (et)
AU (1)	AU732671B2 (et)
BG (1)	BG102669A (et)
BR (1)	BR9707369A (et)
CA (1)	CA2245162A1 (et)
CZ (1)	CZ248798A3 (et)
EE (1)	EE9800234A (et)
IL (1)	IL125446A0 (et)
IS (1)	IS4805A (et)
NO (1)	NO983641L (et)
NZ (1)	NZ331160A (et)
PL (1)	PL328074A1 (et)
SK (1)	SK105698A3 (et)
TR (1)	TR199801511T2 (et)
WO (1)	WO1997028797A1 (et)
YU (1)	YU33298A (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7211582B1 (en)	1994-12-30	2007-05-01	Sepracor Inc.	Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en)	1994-12-30	2007-05-08	Sepracor Inc.	Compositions of descarboethoxyloratadine
GB9723985D0 (en)	1997-11-14	1998-01-14	Zeneca Ltd	Pharmaceutical compositions
DK1041990T3 (da) *	1997-12-23	2006-10-02	Schering Corp	Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
US6384038B1 (en) *	1998-04-14	2002-05-07	Sepracor Inc.	Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en)	1998-04-14	2001-06-19	Sepracor Inc.	Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6194431B1 (en)	1998-04-14	2001-02-27	Paul D. Rubin	Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6262066B1 (en)	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) *	1998-07-27	2001-08-02	Schering Corp	Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
PE20001070A1 (es) *	1998-09-10	2000-10-19	Schering Corp	Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
AU3924500A (en) *	1999-03-29	2000-10-16	Schering Corporation	Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (de)	2000-02-17	2001-08-23	Asta Medica Ag	Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
AU2002227240A1 (en) *	2000-10-30	2002-05-15	Schering Corporation	Treatment and method using loratadine and montelukast
US20020198228A1 (en) *	2001-04-03	2002-12-26	Kaura Sita R.	Composition and method for the treatment of respiratory desease
MY148466A (en) *	2001-10-26	2013-04-30	Merck Frosst Canada Ltd	Granule formulation
WO2004087095A2 (es) *	2003-03-31	2004-10-14	Osmotica Costa Rica, Sociedad Anonima	Dispositivo osmótico que contiene zafirlukast y un antagonista h1
EP1680084A2 (en) *	2003-10-21	2006-07-19	Direct-Haler A/S	A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) *	2004-03-17	2005-09-29	Pfizer Limited	Combination for treating inflammatory diseases
WO2006047427A1 (en)	2004-10-25	2006-05-04	Schering Corporation	M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
TR200806298A2 (tr) *	2008-08-22	2010-03-22	Bi̇lgi̇ç Mahmut	Farmasötik formülasyon
CN102834406A (zh)	2009-06-16	2012-12-19	默沙东公司	作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途
KR101540191B1 (ko) *	2014-02-24	2015-07-28	성균관대학교산학협력단	로라타딘을 포함하는 항염증용 조성물
MA54707A (fr) *	2019-01-10	2021-11-17	Jiangyin Mucocare Pharmaceutical Co Ltd	Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4282233B1 (en) *	1980-06-19	2000-09-05	Schering Corp	Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) *	1984-08-20	1989-09-26	Masaaki Toda	(fused) benz(thio)amides
GB8607294D0 (en) *	1985-04-17	1986-04-30	Ici America Inc	Heterocyclic amide derivatives
US5565473A (en) *	1990-10-12	1996-10-15	Merck Frosst Canada, Inc.	Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) *	1992-04-10	1993-12-14	Merck Frosst Canada, Inc.	Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) *	1992-12-22	1995-12-05	Merck Frosst Canada, Inc.	Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) *	1994-12-30	1997-01-21	Sepracor Inc.	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

1997
- 1997-02-04 IL IL12544697A patent/IL125446A0/xx unknown
- 1997-02-04 KR KR1019980706097A patent/KR19990082367A/ko not_active Withdrawn
- 1997-02-04 JP JP9528627A patent/JPH11504044A/ja active Pending
- 1997-02-04 EE EE9800234A patent/EE9800234A/et unknown
- 1997-02-04 WO PCT/US1997/001799 patent/WO1997028797A1/en not_active Ceased
- 1997-02-04 AU AU22579/97A patent/AU732671B2/en not_active Ceased
- 1997-02-04 NZ NZ331160A patent/NZ331160A/xx unknown
- 1997-02-04 PL PL97328074A patent/PL328074A1/xx unknown
- 1997-02-04 EP EP97905757A patent/EP1014972A4/en not_active Withdrawn
- 1997-02-04 CN CN97192149A patent/CN1210465A/zh active Pending
- 1997-02-04 CA CA002245162A patent/CA2245162A1/en not_active Abandoned
- 1997-02-04 TR TR1998/01511T patent/TR199801511T2/xx unknown
- 1997-02-04 BR BR9707369A patent/BR9707369A/pt not_active Application Discontinuation
- 1997-02-04 SK SK1056-98A patent/SK105698A3/sk unknown
- 1997-02-04 CZ CZ982487A patent/CZ248798A3/cs unknown
1998
- 1998-07-22 IS IS4805A patent/IS4805A/is unknown
- 1998-08-05 BG BG102669A patent/BG102669A/bg unknown
- 1998-08-06 YU YU33298A patent/YU33298A/sr unknown
- 1998-08-07 NO NO983641A patent/NO983641L/no unknown

Also Published As

Publication number	Publication date
CZ248798A3 (cs)	1999-01-13
NO983641D0 (no)	1998-08-07
NO983641L (no)	1998-08-07
AU2257997A (en)	1997-08-28
TR199801511T2 (xx)	1998-10-21
PL328074A1 (en)	1999-01-04
CA2245162A1 (en)	1997-08-14
YU33298A (en)	1999-11-22
JPH11504044A (ja)	1999-04-06
KR19990082367A (ko)	1999-11-25
AU732671B2 (en)	2001-04-26
IS4805A (is)	1998-07-22
WO1997028797A1 (en)	1997-08-14
NZ331160A (en)	2000-07-28
EE9800234A (et)	1998-12-15
EP1014972A1 (en)	2000-07-05
CN1210465A (zh)	1999-03-10
BR9707369A (pt)	1999-07-20
IL125446A0 (en)	1999-03-12
BG102669A (bg)	1999-04-30
EP1014972A4 (en)	2004-12-08

Publication	Publication Date	Title
SK105698A3 (en)	1999-05-07	Method of treatment and pharmaceutical composion
TWI389689B (zh)	2013-03-21	氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
KR100936572B1 (ko)	2010-01-13	안정한 서방출형의 경구 투여용 조성물
AU703242B2 (en)	1999-03-25	Film coated tablet of paracetamol and domperidone
US20150328211A1 (en)	2015-11-19	Pharmaceutical compositions
KR20090057410A (ko)	2009-06-05	약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
CA2780332C (en)	2018-01-30	Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
RU2286784C2 (ru)	2006-11-10	Таблетка, содержащая цетиризин и псевдоэфедрин
JP2007176958A (ja)	2007-07-12	セチリジン及びプソイドエフェドリンを含む錠剤
WO2005004915A2 (en)	2005-01-20	Compositions comprising meloxicam
US20100255082A1 (en)	2010-10-07	Functionally Coated Breakable Tablets
EP0643967A2 (en)	1995-03-22	Pharmaceutical compositions containing analgesic, e.g. morphine, and a laxative, e.g. bisacodyl
WO2005094832A1 (en)	2005-10-13	Compositions comprising meloxicam
US20050038018A1 (en)	2005-02-17	Meloxicam compositions
AU2011339150B2 (en)	2015-09-10	Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
US20070275996A1 (en)	2007-11-29	Use of Statins For The Treatment Of Metabolic Syndrome
WO2010038240A9 (en)	2010-06-03	Pharmaceutical composition comprising nimesulide and levocetirizine
CN107820424A (zh)	2018-03-20	Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型
US20100143471A1 (en)	2010-06-10	Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
JP4344532B2 (ja)	2009-10-14	鼻炎用組成物
JP2006510639A (ja)	2006-03-30	エフレチリジン及びプソイドエフェドリンを含む錠剤
KR20010052895A (ko)	2001-06-25	치료 방법
HK1018744A (en)	2000-01-07	Method of treatment and pharmaceutical composition
AU2023218629A1 (en)	2024-08-01	A pharmaceutical combination of antispasmodic and anxiolytic agent
KR101928849B1 (ko)	2018-12-13	베포타스틴 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 제제